Plant-based gel fast-tracks 'mini-organs' growth

Monash University researchers have created the world’s first bioactive plant-based nanocellulose hydrogel to support organoid growth and help significantly reduce the costs of studies into cancer and COVID-19.

Photo
Researchers have created the world’s first bioactive plant-based nanocellulose hydrogel to support organoid growth for biomedical applications.
Source: Monash University

This discovery by researchers at BioPRIA (Bioresource Processing Institute of Australia), Monash University’s Department of Chemical Engineering and the Monash Biomedicine Discovery Institute will develop organoids cheaper, faster and more ethically. The hydrogel can also improve drug screening and disease modelling for infectious diseases, like COVID-19; metabolic diseases, such as obesity and diabetes; and cancer.

The findings emerge as a promising finding for growth of organoids for essential laboratory testing across the world. With additional testing, this hydrogel could be available to researchers and health professionals across the world in less than 12 months.

Nanocellulose gels cost just cents for every 10ml used, compared to $600 or more for the current gold standard. Above all, nanocellulose gels are completely plant-based, preventing the harvesting of animal organs and unknown biomolecules for any advanced medical testing.

Professor Gil Garnier and Dr Rodrigo Curvello from BioPRIA within Monash University’s Department of Chemical Engineering led the study. “Organoids provide a robust model for key applications in biomedicine, including drug screening and disease modelling. But current approaches remain expensive, biochemically variable and undefined,” Professor Garnier, Director of BioPRIA, said. “These are major obstacles for fundamental research studies and the translation of organoids to clinics. Alternative matrices able to sustain organoid systems are required to reduce costs drastically and to eliminate the unreliability of unknown biomolecules. As nanocellulose hydrogel is animal-free, its composition is controlled perfectly and reproducible – unlike the current process – and fully mimic the human body conditions.”

Organoids are three-dimensional, miniaturised and simplified versions of organs produced in vitro that can replicate behaviours and functionalities of developed organs. Commonly referred to as ‘organs in a dish’ or ‘mini-organs’, organoids are an excellent tool to study basic biological processes. Through organoids, we can understand how cells interact in an organ, how diseases affect them and the effects of drugs in disease reduction.

Organoids are generated from embryonic, adult, pluripotent or induced pluripotent stem cells, as well as from primary healthy or cancerous tissues. For long-term use, organoids are commonly embedded within an Engelbreth-Holm Swarm (EHS) matrix derived from the reconstituted basement membrane of mouse sarcoma.

Currently, organoid culture is dependent of this expensive and undefined tumour-derived material that hinders its application in high-throughput screening, regenerative medicine and diagnostics. “Our study was essentially able to use an engineered plant-based nanocellulose hydrogel that can replicate the growth of small intestinal organoids derived from mice,” Dr Curvello said. “It is essentially made from 99.9% water and only 0.1% solids, functionalised with a single cell adhesive peptide. Cellulose nanofibers are linked with salts that provide the microenvironment needed for small intestinal organoid growth and proliferation. Engineered nanocellulose gel represents a sustainable alternative for the growth of organoids, contributing to reducing the costs of studies on diseases of global concern, particularly in developing countries.”

The research was published in Advanced Science.

Subscribe to our newsletter

Related articles

COVID-19 speeds up microfluidics development

COVID-19 speeds up microfluidics development

With soaring demand for point-of-care testing (POCT), microfluidics has been a pivotal resource as COVID-19 swept across the world.

A microfluidic chip system as alternative to animal experiments

A microfluidic chip system as alternative to animal experiments

Since mid-2019, the Fraunhofer IBMT has been developing an analysis platform as an alternative to animal experiments in drug development.

Using tumor-on-a-chip to find cancer drugs

Using tumor-on-a-chip to find cancer drugs

Researchers have developed a 'tumor-on-a-chip' that can better mimic the environment inside the body, paving the way for improved screening of potential cancer fighting drugs.

Teaching an organ-on-a-chip to see

Teaching an organ-on-a-chip to see

Organ-on-a-chip technology has the potential to revolutionize drug development. Researchers have succeeded in putting various types of tissue onto chips.

3D printing of biological tissue

3D printing of biological tissue

Scientists hope we will soon be using 3D-printed biologically functional tissue to replace irreparably damaged tissue in the body.

Lab-created heart valves can grow with the recipient

Lab-created heart valves can grow with the recipient

Researchers have shown that lab-created heart valves implanted in young lambs for a year were capable of growth within the recipient.

Multicellular liver-on-a-chip for modeling fatty liver disease

Multicellular liver-on-a-chip for modeling fatty liver disease

Researchers have developed a structurally representative liver-on-a-chip model which mimics the full progression sequence of NAFLD.

Shape-changing 4D materials hold promise for bioengineering

Shape-changing 4D materials hold promise for bioengineering

New hydrogel-based materials that can change shape in response to psychological stimuli, such as water, could be the next generation of materials used to bioengineer tissues and organs.

AI, holographic microscopy beat scientists at analyzing immunotherapy​

AI, holographic microscopy beat scientists at analyzing immunotherapy​

AI is helping researchers decipher images from a new holographic microscopy technique needed to investigate a key process in cancer immunotherapy “live” as it takes place.

Popular articles

Subscribe to Newsletter